Novo Nordisk's deal with Korro is worth a total of $530 million in research and development (R&D) funding, milestone payments, royalties, and up-front payments to get the ball rolling. That makes the agreement a meaty but fairly routine one for the big pharma business, and a huge (potentially) once-in-a-lifetime catch for the small biotech.

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve more than 13% weight loss, but that has been over much longer time frames, ranging between 36 to 68 weeks. Terns says that it will move forward with phase 2 trials of its weight-loss drug next year.

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.

The Switzerland-based pharmaceutical company has been trying to crack the weight-loss boom currently dominated by Eli Lilly and Novo Nordisk. Roche shares fell 2.8% in Zurich on T

Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.